Filing Summary
Business Context and Reporting Period
TransMedics Group, Inc. filed a Form 8-K dated March 22, 2021, reporting board and committee appointments under Item 5.02. The filing does not report quarterly or annual operating results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes
- Stephanie Lovell was appointed to the Board of Directors and the Nominating and Corporate Governance Committee, effective March 22, 2021.
- Merilee Raines was appointed to the Compensation Committee, effective March 22, 2021.
Compensation, Outlook, and Other Considerations
- Ms. Lovell will receive an option to purchase 18,000 common shares. One-third vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the following two years, subject to continued board service.
- Ms. Lovell will receive annual cash compensation of $40,000 for board service and $5,000 for service on the Nominating and Corporate Governance Committee, payable quarterly in arrears and prorated for partial quarters.
- Ms. Lovell is eligible for annual equity grants under the company’s non-employee director compensation policy and will enter into a standard indemnification agreement.
- Ms. Raines will receive additional annual cash compensation of $7,500 for Compensation Committee service, payable quarterly in arrears and prorated for partial quarters.
- The filing provides no management guidance, business outlook, contingencies, or operating risk updates.
Key Facts to Verify
- Effective dates and committee assignments for Ms. Lovell and Ms. Raines.
- Terms, vesting schedule, and accounting impact of the 18,000-share option grant.
- Whether subsequent filings disclose additional director compensation, equity grants, or changes to board committee composition.